Uganda & Serum Institute of India

Uganda: Uganda has reported cases of the Bundibugyo strain of Ebola, making it a focus for the World Health Organization's efforts to implement clinical trials for experimental treatments and vaccines.

Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.

Uganda: Uganda has confirmed nine cases of Ebola Bundibugyo, including one death, indicating the regional spread of the outbreak.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.